Cargando…

Anaplastic lymphoma kinase inhibitors and their effect on the kidney

Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non–small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonilla, Marco, Jhaveri, Kenar D, Izzedine, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308093/
https://www.ncbi.nlm.nih.gov/pubmed/35892021
http://dx.doi.org/10.1093/ckj/sfac062
_version_ 1784752913206214656
author Bonilla, Marco
Jhaveri, Kenar D
Izzedine, Hassan
author_facet Bonilla, Marco
Jhaveri, Kenar D
Izzedine, Hassan
author_sort Bonilla, Marco
collection PubMed
description Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non–small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice.
format Online
Article
Text
id pubmed-9308093
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93080932022-07-25 Anaplastic lymphoma kinase inhibitors and their effect on the kidney Bonilla, Marco Jhaveri, Kenar D Izzedine, Hassan Clin Kidney J CKJ Review Lung cancer is the leading cause of cancer-related mortality and approximately 5% of non–small-cell lung cancer (NSCLC) patients are positive for anaplastic lymphoma kinase (ALK) gene rearrangement or fusion with echinoderm microtubule-associated protein-like 4. ALK inhibitors are the mainstay treatment for patients with NSCLC harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update. Several ALK-1 inhibitors are used in clinical practice, including crizotinib, ceritinib and alectinib. According to the package insert and published literature, treatment with several ALK-1 inhibitors appears to be associated with the development of peripheral edema and rare electrolyte disorders, kidney failure, proteinuria and an increased risk for the development and progression of renal cysts. This review introduces the different types of ALK inhibitors, focusing on their detailed kidney-related side effects in clinical practice. Oxford University Press 2022-02-26 /pmc/articles/PMC9308093/ /pubmed/35892021 http://dx.doi.org/10.1093/ckj/sfac062 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle CKJ Review
Bonilla, Marco
Jhaveri, Kenar D
Izzedine, Hassan
Anaplastic lymphoma kinase inhibitors and their effect on the kidney
title Anaplastic lymphoma kinase inhibitors and their effect on the kidney
title_full Anaplastic lymphoma kinase inhibitors and their effect on the kidney
title_fullStr Anaplastic lymphoma kinase inhibitors and their effect on the kidney
title_full_unstemmed Anaplastic lymphoma kinase inhibitors and their effect on the kidney
title_short Anaplastic lymphoma kinase inhibitors and their effect on the kidney
title_sort anaplastic lymphoma kinase inhibitors and their effect on the kidney
topic CKJ Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308093/
https://www.ncbi.nlm.nih.gov/pubmed/35892021
http://dx.doi.org/10.1093/ckj/sfac062
work_keys_str_mv AT bonillamarco anaplasticlymphomakinaseinhibitorsandtheireffectonthekidney
AT jhaverikenard anaplasticlymphomakinaseinhibitorsandtheireffectonthekidney
AT izzedinehassan anaplasticlymphomakinaseinhibitorsandtheireffectonthekidney